Surface-immobilized biomolecules on albumin modified porcine pericardium for preventing thrombosis and calcification.
The search for a noncalcifying tissue material to be used for valve replacement application continues to be a field of extensive investigation. A series of porcine pericardial membranes was prepared by modifying the glutaraldehyde--treated tissues with albumin and subsequently immobilizing bioactive molecules like PGE1, PGI2 or heparin via the carbodiimide functionalities. The in vitro calcification and collagenase degradation of these modified tissues were studied as a function of exposure time. Furthermore, the biocompatibility aspects of such novel interfaces were established by platelet adhesion and fibrinogen adsorption. The results reported in this article propose that the treatment with antiplatelet agents such as albumin, heparin and prostaglandins (PGE1 or PGI2) change the surface conditioning of pericardial tissues, suggesting a possible role of deposited serum components in affecting mineralization process on bioprosthesis. Therefore, it is worthy to hypothesize that besides inhibiting the accumulation of calcium in the devitalized cells, the early formation of a conditioning layer on the bioprosthesis surface may affect salt precipitations, determining the propensity of the implant to calcify. More detailed studies are needed to understand the involvement of plasma proteins and cellular components of the recipient blood in tissue-associated calcification.
Chandy
T
T
Biomedical Engineering Institute, University of Minnesota, Minneapolis 55455, USA. chando25@gold.tc.umn.edu
Das
G S
GS
Wilson
R F
RF
Rao
G H
GH
D000418:Albumins / Q000494:pharmacology; D000527:Alprostadil / Q000494:pharmacology; D000818:Animals; D001672:Biocompatible Materials; D002114:Calcinosis / Q000473:pathology / Q000517:prevention & control*; D009202:Cardiomyopathies / Q000473:pathology / Q000517:prevention & control*; D046508:Culture Techniques; D004797:Enzyme-Linked Immunosorbent Assay; D011464:Epoprostenol / Q000494:pharmacology; D005340:Fibrinogen / Q000032:analysis; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D008422:Materials Testing; D010496:Pericardium / Q000187:drug effects* / Q000648:ultrastructure; D010973:Platelet Adhesiveness / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011336:Probability; D013499:Surface Properties; D013552:Swine; D013927:Thrombosis / Q000517:prevention & control*
D000418:Albumins; D001672:Biocompatible Materials; D010975:Platelet Aggregation Inhibitors; D005340:Fibrinogen; D006493:Heparin; D011464:Epoprostenol; D000527:Alprostadil